PMA device
Surpass Evolve Flow Diverter System
Stryker Neurovascular · Intracranial Aneurysm Flow Diverter (OUT, Class III) · First FDA decision May 20, 2020, newest May 20, 2020Brain aneurysm
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
3
Naming "Surpass Evolve"
MAUDE reports
674
Brand "Surpass Evolve", since 2015
PubMed studies
47
Mentioning "Surpass Evolve"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Surpass Evolve Flow Diverter System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Surpass Evolve Flow Diverter SystemPMA supplement
P170024-S003 · Decided May 20, 2020 · 443 days after receipt · Normal 180 Day Track
Device type: Intracranial aneurysm flow diverter (OUT) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Surpass Evolve", any status and sponsor, newest update first.
- Evolve China PMCF StudyActive, not recruiting
Stryker NeurovascularPublic (SYK)
NCT06368622 · 500 participants (planned) · Start Apr 24, 2024 · Primary completion Nov 2027
Device: Surpass Evolve Flow Diverter System · For: Intracranial Aneurysm
Sites: Beijing, China; Changchun, China; Fuzhou, China · 24 sites in all
- Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter SystemActive, not recruiting
Stryker NeurovascularPublic (SYK)
NCT04195568 · 248 participants · Start Jul 7, 2020 · Primary completion Jul 14, 2025
Device: Surpass Evolve Flow Diverter System · For: Aneurysm, Intracranial
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 37 sites in all
- Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial AneurysmsActive, not recruiting
Yibin FangAcademic, hospital or other
NCT06731946 · 150 participants (planned) · Start Nov 29, 2024 · Primary completion Oct 31, 2025
Device: Flow diverting · For: Intracranial Arterial Aneurysm
Sites: Shanghai, China
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Surpass Evolve", and for the whole product code for context.
This brand
674 reports: 237 malfunction, 422 injury, 15 death
Whole product code OUT
10,961 reports: 7,308 malfunction, 3,152 injury, 499 death
Newest reports for this brand
3008881809-2026-00636 · Received Oct 19, 2026 · Event dated Sep 7, 2026
Device type: Intracranial Aneurysm Flow Diverter (OUT)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hemorrhage/Blood Loss/Bleeding; Perforation
3008881809-2026-00632 · Received Oct 13, 2026 · Event dated Mar 27, 2026
Device type: Intracranial Aneurysm Flow Diverter (OUT)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Stenosis
- SURPASS EVOLVE 4.5MM X 25MM - CEMalfunction
3008881809-2026-00629 · Received Oct 12, 2026 · Event dated Sep 22, 2026
Device type: Intracranial Aneurysm Flow Diverter (OUT)
Device problem as coded: Premature Activation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Surpass Evolve"[tiab]. The summary above synthesizes these.
- Surpass Evolve Flow Diverter for the Treatment of Intracranial Aneurysm: A Systematic Review.
Issa R, Al-Homedi Z, Syed DH, et al. · Brain Sci · 2022Review
- Immediate flow-diversion characteristics of a novel primarily bioresorbable flow-diverting stent.
Muram S, Corcoran R, Cooke J, et al. · J Neurosurg · 2022Research Support, Non-U.S. Gov't
- Efficacy and safety of surpass evolve flow diverters: A systematic review and meta-analysis.
Jazayeri SB, Reda A, Cortese J, et al. · Clin Neurol Neurosurg · 2025Systematic Review, Meta-Analysis
- Safety and efficacy of Surpass Evolve Flow diverter for intracranial aneurysms: A study of 116 patients.
Bibi R, Bankole NDA, Donnard B, et al. · Neuroradiol J · 2024
- Flow Diversion for Intracranial Aneurysms With Incorporated Branch: A Subanalysis From the SEASE International Registry.
Dibas M, Vivanco-Suarez J, Galecio-Castillo M, et al. · Stroke Vasc Interv Neurol · 2024
- The Evaluation of Low-Profile Surpass EvolveTM Flow Diverter for Endovascular Treatment of Distal Cerebral Artery Aneurysms: A Single-Center Experience.
Sayin B, Dereli B, Senol YC, et al. · Turk Neurosurg · 2023
- Stand-alone transarterial flow diversion for treatment of carotid cavernous fistulas.
Abramyan A, Gupta G, Sreenivasan S, et al. · J Stroke Cerebrovasc Dis · 2024Multicenter Study
- Surpass evolve flow diverter in intracranial aneurysms: results from a single-center cohort with extended follow-up.
Jee TK, Choi HW, Yeon JY, et al. · Acta Neurochir (Wien) · 2026Comparative Study
- Nickels and tines: the myth of nickel allergy in intracranial stents.
Vanent KN, Federico EM, Bass DI, et al. · J Neurointerv Surg · 2022
- Comparison of arterial wall integration of different flow diverters in rabbits: The CICAFLOW study.
Forestier G, Cortese J, Bardet SM, et al. · J Neuroradiol · 2024Comparative Study
- Initial Experience with Surpass Evolve Flow Diverter in the Treatment of Intracranial Aneurysms.
Maus V, Weber W, Berlis A, et al. · Clin Neuroradiol · 2021
- Early clinical experience of using the Surpass Evolve flow diverter in the treatment of intracranial aneurysms.
Jee TK, Yeon JY, Kim KH, et al. · Neuroradiology · 2022
Other devices of this type
Also filed under product code OUT.
- Pipeline Flex Embolization Device with Shield TechnologyMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · PMA 2021
- Flow Re-Direction Endoluminal Device (FRED®) SystemMicroVention, Inc. · PMA 2025
- Pipeline Embolization Devices,pipeline Flex Embolization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · PMA 2015
- Pipeline Vantage Embolization Device with Shield TechnologyMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · PMA 2025
- Surpass Streamline Flow DiverterStryker Neurovascular · PMA 2022
- Surpass Elite Flow Diverter SystemStryker Neurovascular · PMA 2024
- FRED X SystemMicroVention, Inc. · PMA 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.